Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Vidutolimod |
| Synonyms | |
| Therapy Description |
Vidutolimod (CMP-001) comprises a Toll-like receptor 9 (TLR-9) agonist encapsulated within a virus-like particle, which may lead to enhanced antitumor immune response and inhibition of tumor growth (PMID: 34326162). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Vidutolimod | CMP-001|CYT003|CYT 003|CYT-003|ARB-1598|QbG10 | TLR9 Agonist 9 | Vidutolimod (CMP-001) comprises a Toll-like receptor 9 (TLR-9) agonist encapsulated within a virus-like particle, which may lead to enhanced antitumor immune response and inhibition of tumor growth (PMID: 34326162). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04807192 | Phase II | Vidutolimod | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | Active, not recruiting | CHE | 0 |